Common stock par value 0.001 per share 1,000,000,000 shares authorized 420,279,879 shares issued and outstanding at september 30, 2026 and december 31, 2025
420,280
420,280
420,280
420,280
Additional paid-in capital
259,357,316
258,475,479
257,043,993
256,179,846
Accumulated other comprehensive loss
-59,635
-59,803
-59,906
-60,191
Accumulated deficit
-266,393,108
-265,126,832
-264,144,266
-262,853,812
Total provectus biopharmaceuticals, inc., stockholders deficit
-6,659,242
-6,275,171
-6,724,587
-6,298,737
Noncontrolling interest in subsidiary
-19,827
-12,393
-6,243
-3,981
Total stockholders deficit
-6,679,069
-6,287,564
-6,730,830
-6,302,718
Total liabilities and stockholders deficit
467,087
1,473,501
577,580
697,502
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.